Spectrum Pharma

Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. Its product pipeline includes: Eflapegrastim, Poziotinib, and IGN002. The company was founded in December 1987 and is headquartered in Henderson, NV.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Spectrum Pharmaceuticals is a biopharmaceutical company that focuses on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus on oncology. It has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development.

BOSTON--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that it has entered into a five-year debt financing agreement with investment affiliates managed by SLR Capital Partners, LLC (SLR) for a term loan facility of up to $65 million. The Company believes this transaction, combined with Spectrum's existing cash balance, provides sufficient capital to opti

Spectrum Pharmaceuticals Announces Debt Financing Agreement with SLR Capital Partners with $30 Million Funded at Closing

BOSTON--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration's (“FDA”) Oncologic Drugs Advisory Committee (“ODAC”) met to review poziotinib for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer (“NSCLC”) harboring HER2 exon 20 insertion mutations. The committee voted

Spectrum Pharmaceuticals Provides Update on Poziotinib Following FDA Oncologic Drugs Advisory Committee Meeting

A Food and Drug Administration advisory committee is set to meet this week to discuss three cancer therapies. The Oncologic Drugs Advisory Committee is set to meet Wednesday to vote whether the benefits of Spectrum Pharmaceuticals Inc.'s SPPI, -1.39% treatment of patients with certain types of non-small cell lung cancer outweigh the risks.

FDA advisory committee to review three cancer drugs this week

Biotechnology firm Spectrum Pharmaceuticals (NASDAQ: SPPI ) recently received regulatory approval for its inflation-reducing injections associated with anti-cancer drugs, thus driving SPPI stock significantly higher on Monday morning. According to the company's Sept.

What Is Going on With Spectrum Pharmaceuticals (SPPI) Stock Today?

Spectrum Pharmaceuticals (SPPI) receives FDA approval for its drug candidate, Rolvedon (eflapergrastim), for treating chemotherapy-induced neutropenia.

Spectrum Pharmaceuticals (SPPI) Gets Nod for Rolvedon Injection

BOSTON--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced data from a poster presentation titled: High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer (NSCLC). The data show that poziotinib is highly active in G778 mutations in both treatment naïve and previously treated patients with NSCLC. The poster titled “High Activity of Poziot

Spectrum Pharmaceuticals Announces Data from Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at ESMO Congress 2022

Microvast Holdings

Seelos Therapeutics

Whether you're a seasoned trader making money with penny stocks or just

Penny Stocks To Buy: The Good, Bad, & Ugly & 3 To Watch Now

BOSTON--(BUSINESS WIRE)--Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON™ (eflapegrastim-xnst) Injection

Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON™ (eflapegrastim-xnst) Injection

BOSTON--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation titled: High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutations in Non-Small Lung Cancer (NSCLC). The poster will be presented at the upcoming European Society for Medical Oncology Congress (ESMO) 2022 that will take place in Paris from September 9-13, 2022. Details of the ESMO poster presenta

Spectrum Pharmaceuticals Announces Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at the Upcoming ESMO Congress 2022

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Michael Grabow - SVP, Corporate Strategy and Operations Thomas J. Riga - President and CEO Francois J.

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Thomas Riga on Q2 2022 Results - Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Spectrum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Spectrum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the second quarter 2022 financial results and provide a corporate update on Thursday, August 11, 2022 at 8:30 a.m. Eastern/5:30 a.m. Pacific. Conference Call and Webcast: Thursday, August 11, 2022 @ 8:30 a.m. Eastern/5:30 a.m. Pacific To access the live call by phone, please go to this

Spectrum Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update

Glaukos

Jazz Pharmaceuticals

JAZZ, GKOS and SPPI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13, 2022.

Best Momentum Stocks to Buy for July 13th

Epizyme

NRX Pharmaceuticals

Trevena

Penny stocks to watch under $1 right now The post Hot Penny Stocks Under $1 To Watch In June appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks Under $1 To Watch In June

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in two upcoming investor conferences: A fireside chat presentation at the Jefferies Healthcare Conference in New York from 1 to 1:25 p.m. ET on Thursday, June 9, 2022; and, A fireside chat presentation at the JMP Securities Life Sciences Conference in New York from 9 to 9:25 a.m. ET on Thursday

Spectrum Pharmaceuticals to Participate in Two Upcoming Investor Conferences

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced additional exploratory data for poziotinib in non-small cell lung cancer (NSCLC) patients harboring HER2 exon 20 insertion mutations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from June 3-7. In poziotinib treated patients with advanced NSCLC harboring HER2 exon 20 insertion mu

Spectrum Pharmaceuticals to Present Data at 2022 ASCO Highlighting the Potential Predictive Capabilities of ctDNA as a Biomarker for Poziotinib Treatment Response

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the upcoming H.C. Wainwright Global Investment Conference, to be held virtually and in Miami Beach from May 23-26, 2022. A presentation will be available on the Investor Relations section of the company's website at http://investor.sppirx.com/events-and-presentations beginning on May 24, 202

Spectrum Pharmaceuticals to Participate in H.C. Wainwright Global Investment Conference

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI ) Q1 2022 Results Conference Call May 12, 2022 4:30 PM ET Company Participants Michael Grabow - Senior Vice President of Corporate Strategy and Operations Thomas Riga - President and CEO Francois Lebel - Chief Medical Officer Conference Call Participants Maury Raycroft - Jefferies Edward White - H.C. Wainwright Mayank Mamtani - B.

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Thomas Riga on Q1 2022 Results - Earnings Call Transcript

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended March 31, 2022 and provided a corporate update. “We anticipate FDA approvals later this year for poziotinib and eflapegrastim. In the first quarter, we initiated a confirmatory study and presented additional positive scientific data for poziotinib. The resubmitted BLA fo

Spectrum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Nora Brennan as Chief Financial Officer effective May 25, 2022. Ms. Brennan has served on Spectrum's Board of Directors and as Chairperson of the Audit Committee since December 2020, and will relinquish her Board duties to assume this new role. “We are thrilled to have Ms. Brennan join Spectrum's senior lead

Spectrum Pharmaceuticals Appoints Nora E. Brennan as Chief Financial Officer

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2022 financial results and provide a corporate update on Thursday, May 12, 2022 at 4:30 p.m. Eastern/1:30 p.m. Pacific. Conference Call and Webcast: Thursday, May 12, 2022 @ 4:30 p.m. Eastern/1:30 p.m. Pacific Domestic: (877) 837-3910 International: (973) 796-5077 Con

Spectrum Pharmaceuticals to Report First Quarter 2022 Financial Results and Provide Corporate Update

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Brittany Bradrick to its Board of Directors. Brittany is an accomplished leader with 25 years of finance, strategy and corporate development experience. “It's my pleasure to welcome Brittany to our Board of Directors at this important next stage in Spectrum's evolution,” stated William Ashton, Chairman of th

Spectrum Pharmaceuticals Appoints Brittany K. Bradrick to Board of Directors

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the open-label Phase III CHAMPION-NMOSD trial showed that ULTOMIRIS® (ravulizumab-cwvz) achieved a statistically significant and clinically meaningful reduction in the risk of relapse in adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) compared to the external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial. ULTOMIRIS, the first and only long-acting C5 compl

ULTOMIRIS® (ravulizumab-cwvz) Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults with Neuromyelitis Optica Spectrum Disorder

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the resubmitted Biologics License Application (BLA) for eflapegrastim has been accepted for filing. The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) goal date of September 9, 2022. Spectrum is seeking an indication to decrease the incidence of infection, as manifested by febrile

Spectrum Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for Eflapegrastim

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced abstract acceptance with a poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to be held in New Orleans from April 8-13, 2022. Session title and information for the poster is listed below and is now available on the AACR online itinerary planner. Predictive ability of circulatin

News for Spectrum Pharma Stock (SPPI)